Fintel reports that on August 10, 2023, Citigroup preserved protection of Merus N.V (NASDAQ: MRUS) with a Buy suggestion. Expert Price Forecast Suggests 103.11% Upside As of August 2, 2023, the typical 1 year cost target for Merus N.V is 46.51. The projections vary from a low of 35.35 to a high of $51.45. The typical cost target represents a boost of 103.11% from its most current reported closing cost of 22.90. See our leaderboard of business with the biggest cost target upside. The forecasted yearly income for Merus N.V is 41MM, a boost of 0.05%. The predicted yearly non-GAAP EPS is -3.45. What is the Fund Sentiment? There are 169 funds or organizations reporting positions in Merus N.V. This is a boost of 14 owner(s) or 9.03% in the last quarter. Typical portfolio weight of all funds committed to MRUS is 0.57%, a boost of 14.91%. Overall shares owned by organizations increased in the last 3 months by 2.99% to 39,062 K shares. The put/call ratio of MRUS is 1.13, suggesting a bearish outlook. What are Other Shareholders Doing? Wellington Management Group Llp holds 3,137 K shares representing 6.30% ownership of the business. In it’s previous filing, the company reported owning 3,690 K shares, representing a reduction of 17.63%. The company reduced its portfolio allowance in MRUS by 0.07% over the last quarter. Bvf holds 2,978 K shares representing 5.98% ownership of the business. No modification in the last quarter. Commodore Capital holds 2,950 K shares representing 5.92% ownership of the business. In it’s previous filing, the company reported owning 2,733 K shares, representing a boost of 7.37%. The company increased its portfolio allowance in MRUS by 29.72% over the last quarter. Federated Hermes holds 2,639 K shares representing 5.30% ownership of the business. In it’s previous filing, the company reported owning 3,924 K shares, representing a decline of 48.72%. The company reduced its portfolio allowance in MRUS by 60.04% over the last quarter. Deerfield Management Company, L.p. holds 2,380 K shares representing 4.78% ownership of the business. No modification in the last quarter. Merus N.V Background Information (This description is offered by the business.) Merus is a clinical-stage oncology business establishing ingenious full-length human bispecific and trispecific antibody therapies, described as Multiclonics ®. Multiclonics ® are produced utilizing market basic procedures and have actually been observed in preclinical and scientific research studies to have numerous of the very same functions of traditional human monoclonal antibodies, such as long half-life and low immunogenicity. Extra reading: Employment Agreement, dated since June 14, 2023, by and in between Merus United States, Inc. and Gregory D. Perry. Work Agreement, dated February 24, 2023, by and amongst Merus United States, Inc., the Registrant and Hui Liu DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Disclaimer This discussion (consisting of any oral commentary that accompanies this discussion) consists of positive declarations within the significance of the Private Securities Litigation Reform Act of 1995. All declarations consisted of in this presentat Employment Agreement, dated January 1, 2023, by and in between Merus United States, Inc. and Peter Silverman This story initially appeared on Fintel. The views and viewpoints revealed herein are the views and viewpoints of the author and do not always show those of Nasdaq, Inc.
Citigroup Maintains Merus N.V (MRUS) Buy Recommendation
